Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Transplantation. 2012 Feb 15;93(3):319–324. doi: 10.1097/TP.0b013e31823f7eea

FIGURE 2.

FIGURE 2

Graphic depiction of change in class I donor-specific antibodies (DSA) mean fluorescence intensity (MFI) before and after treatment with bortezomib. (Shaded areas) Treatment with bortezomib. iDSA was the DSA with highest MFI. There was a 56%to97%reduction in class I iDSA MFI after treatment with bortezomib. (a) After treatment with plasmapheresis, IVIg and rituximab 2 ½ months earlier iDSA Cw5 remained elevated but showed an acute precipitous reduction with bortezomib treatment followed by an increase at 2 weeks posttreatment. Retreatment resulted in an acute reduction in iDSA Cw5. (b) Plasmapheresis and IVIg given less than 1 week before had no effect on iDSA B44 MFI, which decreased over a 20-day period and then subsequently declines. This is accompanied by a reduction in DSA A2 MFI. (c) After an initial increase in iDSA despite plasmapheresis on five of the preceeding 7 days, there is an acute and sustained reduction in iDSA Cw7 after treatment with bortezomib. (d) After an initial reduction in iDSA with institution of ECMO and plasmapheresis on the 5 days before treatment, there was a further sustained reduction of iDSA B51 with bortezomib treatment.